News

With this election, Mr Represas will become one of 13 outside directors on the 14-member board. Mr Represas will stand for election by the company’s stockholders in April

The devices are approved for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries, and are marketed by the Bard peripheral vascular division,

Mr Slansky has served for the past six years as the president and CFO of Poway, California-based SpaceDev, a publicly traded space technology/aerospace company. Mr Slansky has received

The new contract is effective for one year with an auto-renewal provision. Gregory Weishar, CEO of PharMerica, said: “Golden Living is a valued client and we are pleased

Denmark-based biopharmaceutical company NeuroSearch has signed an agreement with Eli Lilly to form a three-year drug discovery and development alliance to investigate a defined number of undisclosed ion

Teva Pharmaceutical Industries, a generic pharmaceutical company, has posted a net loss of $688 million, or $0.88 per diluted share, in the fourth quarter of 2008, compared to

Teijin Pharma and Takeda Pharmaceutical Company have announced that Teijin Pharma’s US licensee for febuxostat and Takeda’s wholly owned subsidiary, Takeda Pharmaceuticals North America, has received the FDA’s

Roche has announced that a Phase III study investigating the efficacy and safety of extended preventative therapy with Valcyte met its primary endpoint of reducing the number of

Under the terms of one of two types of purchase agreements, Affymax will sell 2.84 million newly issued shares of its common stock at a purchase price of